Fms related receptor tyrosine kinase 4. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Lenvatinib CHEMBL1289601 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 209 |
| Anlotinib CHEMBL4303201 |
Vascular endothelial growth factor receptor 3 inhibitor Inhibitor Small molecule |
✓ Both | 76 |
| Fruquintinib CHEMBL4303214 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 51 |
| Regorafenib CHEMBL1946170 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 43 |
| Surufatinib CHEMBL4297190 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 25 |
| Axitinib CHEMBL1289926 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 24 |
| Sunitinib CHEMBL535 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Vascular endothelial growth factor receptor 3 inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Sorafenib CHEMBL1336 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Famitinib CHEMBL1278146 |
Vascular endothelial growth factor receptor 3 inhibitor Inhibitor Small molecule |
ChEMBL only | 11 |
| Cediranib Maleate CHEMBL2103798 |
Inhibits FLT4 Primary target Small molecule |
Guide to Pharmacology only | 10 |
| Pazopanib CHEMBL477772 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 10 |
| Nintedanib CHEMBL502835 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Chiauranib CHEMBL5095033 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 3 |
| Sunitinib Malate CHEMBL1567 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Vandetanib CHEMBL24828 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Tivozanib CHEMBL1289494 |
Vascular endothelial growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Non-small cell lung carcinoma | 9 | Phase 3 |
| Breast cancer | 8 | Phase 3 |
| Acute myeloid leukemia | 7 | Phase 3 |
| Colorectal cancer | 7 | Phase 3 |
| Hepatocellular carcinoma | 7 | Phase 3 |
| Fallopian tube cancer | 6 | Phase 3 |
| Age-related macular degeneration | 5 | Phase 3 |
| Kidney cancer | 5 | Phase 3 |
| Primary peritoneal carcinoma | 5 | Phase 3 |
| Renal cell adenocarcinoma | 5 | Phase 3 |
| Glioblastoma | 5 | Phase 2/3 |
| Cancer | 4 | Phase 3 |
| Cervical cancer | 4 | Phase 3 |
| Clear cell renal carcinoma | 4 | Phase 3 |
| Endometrial cancer | 4 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
